N-glycan Analysis in Molecular Medicine: Innovator and Biosimilar Protein Therapeutics

Author(s): Beata Borza, Laszlo Hajba*, Andras Guttman

Journal Name: Current Molecular Medicine

Volume 20 , Issue 10 , 2020

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


The market segment of new biological drugs (monoclonal antibodies, fusion proteins, antibody-drug conjugates, and new modality protein therapeutics) is rapidly growing, especially after the patent expiration of the original biologics, initiating the emergence of biosimilars. N-glycosylation of therapeutic proteins has high importance on their stability, safety, immunogenicity, efficacy, and serum half-life. Therefore, Nglycosylation is considered to be one of the critical quality attributes. Consequently, it should be rigorously monitored during the development, manufacturing, and release of glycoprotein biologicals. In this review, first, the regulatory considerations for biosimilars are shortly summarized, followed by conferring the analytical techniques needed for monitoring and characterization of the N-glycosylation of biological drugs. Particular respect is paid to liquid phase separation techniques with high sensitivity and highresolution detection methods, including laser-induced fluorescence and mass spectrometry.

Keywords: Biosimilar, biosimilarity, biotherapeutics, glycosylation, antibody, analysis, capillary electrophoresis, high performance liquid chromatography.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Published on: 03 December, 2020
Page: [828 - 839]
Pages: 12
DOI: 10.2174/1566524020999201203212352
Price: $65

Article Metrics

PDF: 31